[8-K] Autodesk Inc Reports Material Event

Rhea-AI Filing Summary

Advantech Capital L.P. and three affiliated Cayman entities filed Amendment No. 2 to their Schedule 13D on Sinovac Biotech Ltd. (ticker SVA) dated 14 July 2025.

• Ownership: The four reporting persons jointly hold 5,851,423 common shares, equal to 8.14 % of Sinovac’s 71,860,702 outstanding shares (per the 2023 Form 20-F). Voting and dispositive power are shared; none is held solely.
• Key Event Update (Item 4): • 7 July 2025 – Antigua High Court issued an injunction blocking several shareholders, including the reporting persons, from voting at a requisitioned Special Meeting.
  • 8 July 2025 – Eastern Caribbean Court of Appeal stayed that injunction, clearing the way for the meeting.
  • Same day – The Special Meeting proceeded despite an attempt to adjourn. Shareholders approved both proposals submitted by SAIF Partners IV L.P. and elected SAIF’s slate of directors.
  • Yumin Qiu, a partner at Advantech Capital, was elected and accepted a board seat.
• Continuing Dispute: On 10 July 2025 the ousted directors issued a press release disputing the vote; on 11 July 2025 the newly elected board announced its first meeting, signalling an ongoing governance contest.
• Future Intentions: The filers state they have no present plan that would trigger the additional transactions listed in Item 4(a)-(j) of Schedule 13D, but may reconsider depending on Sinovac’s performance and discussions with other shareholders. They expressly disclaim forming a “group” with other holders.
• Administrative Details: All signatures were executed by Yan Yang as authorised signatory/director for each entity.

The filing signals an activist milestone: a 8 % holder has helped change Sinovac’s board composition, yet litigation and duelling press releases highlight unresolved control issues that could affect corporate strategy and share-holder value.

Positive

• Advantech and affiliates secured a board seat for partner Yumin Qiu, signalling increased influence over Sinovac’s strategic direction.
• The group holds 5.85 million shares, representing a significant 8.14 % economic interest that aligns board participation with ownership.
• Court of Appeal stay enabled shareholder voting, demonstrating the group’s ability to navigate legal challenges successfully.

Negative

• Litigation and conflicting press releases from ousted directors create uncertainty around the validity of the Special Meeting results.
• An earlier injunction highlights ongoing legal exposure and potential costs until governance issues are fully resolved.

Insights

Securities Analyst

TL;DR: 8.14 % stake, successful board seat, legal dispute persists—potential governance catalyst for SVA.

The amendment confirms Advantech’s meaningful 8 % position and its active participation in reshaping Sinovac’s board through SAIF’s proposals. Activist involvement can drive strategic or capital-allocation changes, often unlocking value. However, the contested legitimacy of the vote and prior injunction introduce headline and litigation risk, which may create short-term volatility. No immediate plan to raise or cut the stake is disclosed, limiting visibility on further accumulation or exit. Overall, the development is potentially value-enhancing but remains contingent on the new board gaining uncontested control.

Corporate Governance Expert

TL;DR: Court stay allowed contested meeting; board now split between old and new factions—material governance overhang.

The stay of the Antigua injunction illustrates how cross-border legal venues can complicate shareholder rights. While the meeting approved SAIF’s slate, the ousted directors’ subsequent press release signals refusal to concede, raising the spectre of continued litigation in Caribbean courts and possible delay in implementing new governance. Advantech’s disclosure complies with Item 4, yet its disclaimer of group status could become a focus if regulators or courts probe coordinated action. Until the board’s legitimacy is resolved, Sinovac faces execution risk in decision-making and potential regulatory scrutiny, impacting investor confidence.

false 0000769397 0000769397 2025-07-14 2025-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

July 14, 2025

Autodesk, Inc.

(Exact name of registrant as specified in its charter)

Delaware		000-14338		94-2819853
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

One Market Street, Ste. 400
San Francisco, California		94105
(Address of principal executive offices)		(Zip Code)

(415) 507-5000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		ADSK		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosures.

On July 14, 2025, Autodesk provided the following business update: We are confident in our plans to drive long-term shareholder value and remain focused on executing our established strategic priorities in cloud, platform, and AI; optimizing our sales and marketing to drive higher margins; and allocating capital to organic investment, targeted and tuck-in acquisitions, and continuing our share repurchase program as our free cash flow grows.

The information in this current report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Safe Harbor Statement

This current report on Form 8-K contains forward-looking statements that involve risks and uncertainties, including the statements in the first paragraph above. There are a significant number of factors that could cause actual results to differ materially from statements made in this current report on Form 8-K, including: our strategy to develop and introduce new products and services and to move to platforms and capabilities, exposing us to risks such as limited customer acceptance (both new and existing customers), costs related to product defects, and large expenditures; global economic and political conditions, including changes in monetary and fiscal policy, foreign exchange headwinds, recessionary fears, supply chain disruptions, resulting inflationary pressures and hiring conditions; geopolitical tension and armed conflicts, economic and regulatory uncertainty including tariffs and trade wars, and extreme weather events; costs and challenges associated with strategic acquisitions and investments; our ability to successfully implement and expand our transaction model and our sales and marketing optimization; dependency on international revenue and operations, exposing us to significant international regulatory, economic, intellectual property, collections, currency exchange rate, taxation, political, and other risks, including risks related to the war against Ukraine launched by Russia and our exit from Russia and the current conflict between Israel and Hamas; inability to predict subscription renewal rates and their impact on our future revenue and operating results; existing and increased competition and rapidly evolving technological changes; fluctuation of our financial results, key metrics and other operating metrics; our transition from up front to annual billings for multi-year contracts; deriving a substantial portion of our net revenue from a small number of solutions, including our AutoCAD-based software products and collections; any failure to successfully execute and manage initiatives to realign or introduce new business and sales initiatives, including our new transaction model for Flex; net revenue, billings, earnings, cash flow, or new or existing subscriptions shortfalls; social and ethical issues relating to the use of artificial intelligence in our offerings; our ability to maintain security levels and service performance meeting the expectations of our customers, and the resources and costs required to avoid unanticipated downtime and prevent, detect and remediate performance degradation and security breaches; security incidents or other incidents compromising the integrity of our or our customers’ offerings, services, data, or intellectual property; reliance on third parties to provide us with a number of operational and technical services as well as software; our highly complex software, which may contain undetected errors, defects, or vulnerabilities; increasing regulatory focus on privacy issues and expanding laws; governmental export and import controls that could impair our ability to compete in international markets or subject us to liability if we violate the controls; protection of our intellectual property rights and intellectual property infringement claims from others; the government procurement process; fluctuations in currency exchange rates; our debt service obligations; and our investment portfolio consisting of a variety of investment vehicles that are subject to interest rate trends, market volatility, and other economic factors. Our estimates as to tax rate are based on current interpretations of existing tax law and could be affected by changing interpretations, further guidance, and additional tax legislation. Further information on potential factors that could affect the financial results of Autodesk are included in Autodesk’s Form 10-K and subsequent Forms 10-Q, which are on file with the U.S. Securities and Exchange Commission. Autodesk disclaims any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AUTODESK, INC.
	By:	/s/ Janesh Moorjani
		Janesh Moorjani Executive Vice President and Chief Financial Officer

Date:  July 14, 2025

2

FAQ

How many Sinovac (SVA) shares does Advantech Capital own?

The filing shows 5,851,423 common shares, representing 8.14 % of Sinovac’s outstanding stock.

What court actions affected Sinovac’s Special Meeting in July 2025?

On 7 July 2025 the Antigua High Court issued an injunction barring voting; on 8 July 2025 the Eastern Caribbean Court of Appeal stayed that order.

Were SAIF Partners’ proposals approved at the Special Meeting?

Yes. Shareholders— including Advantech via proxy— approved both SAIF proposals and elected its director nominees.

Who from Advantech Capital joined Sinovac’s board?

Advantech partner Mr. Yumin Qiu was elected and accepted a position as director.

Does Advantech plan further transactions with Sinovac?

The group states it has no present plans triggering Item 4(a)-(j) actions but may reconsider based on future conditions.

Where is Sinovac Biotech’s principal executive office located?

The address is No. 39 Shangdi Xi Road, Haidian District, Beijing, China 100085.